News Release

For Release: Immediately

Contact: Stefan Bircher
Global Market Development Manager
Phone 216 896 2741
stefan.bircher@parker.com

Indego® Exoskeleton Included in Revised Insurance Policy from Cigna

Insurer to review submissions on a case-by-case basis for FDA-approved exoskeletons for home use

CLEVELAND, March 22, 2018 - Parker Hannifin Corporation (NYSE:PH), the global leader in motion and control technologies, today announced its Indego exoskeleton is now eligible for insurance coverage through a recently revised policy from Cigna Corporation.

According to the new policy Cigna will review submissions for FDA-approved exoskeletons, including Indego, for use as a medical device by individuals with spinal cord injury on a case-by-case basis. This marks the first commercial insurer in the United States to initiate a national policy change for coverage of personal use exoskeleton technology.

This policy shift to case-by-case claim review reflects growing research and literature demonstrating improved health outcomes and increased quality of life for individuals with spinal cord injury from regular use of powered exoskeleton systems. Cigna's revised policy is expected to be published this summer.

"This policy change represents a significant step forward in improving access of exoskeleton technology to patients living with limited mobility due to spinal cord injury," said Achilleas Dorotheou, head of the human motion and control business unit for Parker.

In June 2018, the U.S. Department of Veterans Affairs issued its own revised policy which expanded its protocol, originally issued in 2015, for purchasing personal use exoskeletons for spinal cord injured veterans to all FDA-approved devices for home use.

About Indego

With dedicated therapy and personal use exoskeletons, Indego provides solutions that address the complete continuum of care – from acute rehabilitation to home and community ambulation. Indego Therapy is cleared by the FDA for use with spinal cord injury patients with injury levels

C7 to L5, and for individuals with hemiplegia (with motor function of 4/5 in at least one upper extremity) due to cerebrovascular accident (CVA) to perform ambulatory functions in rehabilitation institutions. Indego Personal is cleared by the FDA to enable individuals with spinal cord injury at levels T3 to L5 to perform ambulatory functions in their home and community. Indego Therapy and Indego Personal are also commercially available in Europe, having received the CE Mark in November 2015. To learn more about Indego Therapy or Indego Personal, visit www.indego.com

About Parker Hannifin

Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Learn more at www.parker.com or @parkerhannifin.

###